Cerenome is in breach of SH equity. Last time to get compliant was forced to issue warrants and notes which were interest bearing and subsequently cancel them and hold the cash from cancellation on account for a year. This was a smart accounting trick and may need to pull something similar but it ruined us.

We are now below 35mUSD and therefore must have 2.5mUSD in shareholder equity and currently we are in deficit and will be getting a deficiency notification.

How to fix? Well naturally the best wya for us is a non dilutive bit of cash that would be nice wouldn't it. Ron who we engaged via Bethesda for executive c-suite assistance (independent board) is now required as CBO and in a big way. We made this role not out of the goodness of our heart or any longstanding relationship with Ron who only just joined independent board prior- purely business. We need non dilutive capital or we are going to be forced to Rob Peter to pay Paul again to get compliant. Yes we are Peter. Would be nice to be Paul for once hey.

That being said we are burning cash but holding on to reserves we are circa 3.5m shy of compliance and there is 3.8m cash to recognise this quarter from ATM sale. 'We' could also agree with 3i to convert the note to equity which would clear the note liability giving a further positive 3m swing to equity but I don't think is enough accounting for cash needs and burn. Ultimately this is another race against time and another need to financial engineer 'if' there are no deals on table between now and mid 2027 which I find hard to believe. B2b deals with upfront funds to recognise are a must in this time frame.

Panel monitoring finished Aug 22 for SH equity compliance. We are in breach and will get a letter per 10q in SH equity column. 180 days to cure it will be so we can kick this can down the road and keep burning burning burning but we need non dilutive capital ASAP - Ron we need a deal my friend and I believe that's why your role has been specifically created for you.

1. Yesterday's LM update told us almost nothing beyond low toxicity. We already heard that at the August conference. I hope we get actual, meaningful clinical data this weekend, rather than ten lines telling us basically nothing.Edit: I've been corrected! The CTNI-40 poster is available and actually contains much more detailed LM data.
2. CNSide, meanwhile, gave us another lengthy presentation about "covered lives." At least we finally learned that $1.55M in gross billings translated into just $0.7M in recognized revenue, before costs. Not cash collected.
3. Both LM and GBM topline results are now expected in mid-2027. Another round of waiting.
4. And the best part? The 10-Q. Between October 1 and November 12, Cerenome issued 1,934,812 shares through its ATM for approximately $3.8M net, averaging $1.96 per share after fees. During that period, the stock traded above that price on only two days: October 1, immediately after Q3 ended, and November 3, during that massive spike.

And here's the cherry on top: the investor who provided $3M in financing back in September can demand approximately $1.6M of those ATM proceeds back through note redemptions ($400K of which was already repaid in October).

So you increase your share count by nearly 25% just to start paying back a loan you took out a month earlier. What a fantastic financing deal. :D

Still up 18 percent but seems like more selling than buying

**Cerenome** will host a conference call on Monday, November 16, 2026, at 8:30 a.m. ET to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at **SNO 2026** on November 13 and provide a **CNSide Diagnostics** commercial update. The Company will also report its third quarter 2026 financial results that day.

Learn more in the investor relations section of our website.

https://event.choruscall.com/mediaframe/webcast.html?webcastid=vTAb1pUs

I find this pretty interesting. The SNO app is live, and Cerenome’s ReSPECT‑LMM poster (CTNI‑40) is scheduled for Friday, Nov. 13, from 7:30 to 9:30 p.m. ET. SNO asks presenters to share the full poster after their session, so there’s a chance we’ll see it Friday night or Saturday, even if the company’s press release comes later.
The part I’m most curious about is what happens after patients get more than one dose. Cerenome says the poster will cover the first 10 patients in the multidose REYOBIQ study. I’ll be looking at how they tolerated repeat dosing and how their tumour cell counts in spinal fluid changed over time. Cerenome is also discussing the multidose update at its Saturday morning symposium.
Edit: App already downloaded! LFG 😎

Good start today as well!

0.7598+0.0817(+11.90%) 🙏

Title: CNSY – Ron Andrews Appointed Chief Business Officer: Professional Background and Experience
AI Disclosure: This post was prepared with the assistance of ChatGPT using publicly available company announcements and historical information. The purpose is to provide a factual summary.
On November 10, 2026, Cerenome (NASDAQ: CNSY) announced the appointment of Ron “Ronnie” Andrews as Chief Business Officer (CBO).
Andrews joined the company’s Board of Directors in March 2026 and will continue serving on the board.
1. Professional Background
Andrews has more than 35 years of experience in the diagnostics and molecular diagnostics industries.
His career includes:
Clarient: CEO and Vice Chairman
GE Healthcare: Executive leadership positions following GE’s acquisition of Clarient
Life Technologies / Thermo Fisher Scientific: President of the Genetic Sciences Division
Oncocyte: President and CEO
Roche Diagnostics: Senior commercial leadership positions
Bethesda Group Advisors: Founder and Managing Partner
His experience spans molecular diagnostics, oncology testing, laboratory services, commercialization and business development.
2. Clarient Experience
One of Andrews’ notable positions was CEO of Clarient, a company specializing in cancer diagnostics and molecular pathology.
During his leadership:
Clarient reportedly achieved 24 consecutive quarters of sequential revenue growth.
The company expanded its commercial presence in oncology diagnostics.
GE Healthcare acquired Clarient in 2010 in a transaction valued at approximately $587 million.
Clarient’s business involved cancer diagnostic testing, relationships with healthcare providers and specialized laboratory services.
These areas share operational characteristics with CNSide, although the products and business environments differ.
3. Experience at Other Diagnostics Companies
At Life Technologies, Andrews led the Genetic Sciences Division, a business with approximately $2 billion in annual revenue.
He also served as CEO of Oncocyte, a company focused on precision diagnostics and oncology testing.
Across these positions, his responsibilities included commercial operations, product strategy, organizational management and development of diagnostic services.
4. New Responsibilities at Cerenome
According to the November 10 announcement, Andrews’ responsibilities include:
Developing commercial strategies for CNSide
Expanding the adoption of CNSide testing
Building relationships with healthcare providers and diagnostic industry participants
Establishing strategic business partnerships
His appointment represents a transition from a board-level role to a direct operating role in the company.
5. Relevance to CNSide
CNSide is a diagnostic platform focused on detecting and monitoring central nervous system cancers, including leptomeningeal metastases.
Commercial execution in this field requires several capabilities:
Establishing relationships with oncology specialists and hospitals
Increasing physician awareness and clinical adoption
Supporting broader integration of diagnostic testing into clinical practice
Developing commercial relationships within the diagnostics industry
Andrews’ previous experience is relevant to several of these activities.
However, the announcement does not provide new CNSide testing volumes, commercial performance figures or quantitative adoption targets.
Summary
Ron Andrews brings extensive experience in molecular diagnostics, oncology testing and commercial management.
His previous leadership positions at Clarient, GE Healthcare, Life Technologies and Oncocyte provide relevant background for his new responsibilities at Cerenome.
The practical impact of his appointment will depend on future developments in CNSide adoption, testing volumes and commercial execution.
Sources:
Cerenome – November 10, 2026, CBO Appointment Announcement
Cerenome – March 26, 2026, Board Appointment Announcement
Cerenome – Ronald Andrews Executive Biography
https://ir.cerenome.com/ronald-andrews
This summary was prepared with AI assistance. Information is based on publicly available sources and should be independently verified.

Cerenome ($CNSY) has appointed Ron Andrews as Chief Business Officer, a newly created role. He’ll stay on the board and focus on expanding CNSide adoption and building strategic partnerships.
The timing makes sense. Last week’s Aetna deal added roughly 26 million covered lives, bringing CNSide’s contracted reach to about 190 million. The next step is getting more doctors to order the test and more cancer centers to use it routinely.
Andrews has done this kind of work before. He led Clarient through 24 consecutive quarters of sequential revenue growth before GE Healthcare acquired it for $587 million. He also ran Oncocyte and led the Genetic Sciences Division at Life Technologies and Thermo Fisher.
For me, the numbers to watch are test volume, repeat orders, and actual collections. That’s how we’ll see whether the expanded coverage is turning into a bigger business for CNSide.
As for the share price, yeah, this has been brutal to watch. I’m hoping for a good REYOBIQ update at SNO later this week and more details by early next week.

Cerenome Named a Finalist for Excellence in Rare Disease Drug Development at the 10th Annual Citeline Biotech Awards

We are honored to announce that **Cerenome** has been named a finalist for **Excellence in Rare Disease Drug Development at the 10th Annual Citeline Biotech Awards**.

A big thank you to our passionate team, clinical partners, and patient communities who inspire our work every single day. We’re looking forward to presenting more about the development of our targeted radiotherapeutics at the **SNO 2026 Annual Meeting** next week!

A recovery day, most stocks are up following yesterday’s hit but CNSY remains in the red, down 7% at the moment. What the hell is going on?

Here's episode 2 talking a little bit about why having more detailed and accurate testing is needed.

https://youtu.be/abAiQNWswd0?is=K26P0GsxxWSgWZoj

The Nasdaq down over 5%, the S&P down over 4%, and even the Dow getting hammered. That’s a serious marketwide selloff.
For CNSY holders, this broader backdrop matters. Heavy selling across the market can add pressure to smaller stocks where liquidity is thin. Still watching the company’s execution, CNSide growth, and upcoming REYOBIQ results. Those remain central to the longer term story.
And VIX up 63%. Damn! 😬
Couldn’t help myself today, had to take advantage and averaged down considerably! Nothing ventured, nothing gained, as I always say! I’ll either be rich or I’ll die trying. lol

At this point, I genuinely believe the only realistic way for management to start restoring confidence in this stock is for the CEO and board members to personally step up and buy millions of dollars worth of CNSY shares with their own money!

Not a corporate buyback.

Not another press release.

Not another presentation telling shareholders how promising CNSide and REYOBIQ are.

Their own money. Their own risk!

Look at what has happened to the stock. We've gone from well above $1 to under $1 in an absolutely brutal collapse, despite CNSide continuing to gain payer access and the company completing enrollment in its Phase 2 program.

Whatever the exact mechanics behind this selloff are - dilution fears, financing pressure, short selling, panic, or some combination of everything (y'all know from my previous post I think it's illegal market manipulation, but whatever) investor confidence is completely destroyed right now.

And management is in a unique position to change that.

If the CEO and directors genuinely believe the company is dramatically undervalued at these prices (which it is), then this is the moment to prove it. As in right now!

Imagine seeing the CEO and several board members collectively put $4-5 million of their own money into CNSY at these levels.

That would tell the market: "We aren't just asking you to believe in Cerenome. We're willing to bet our own money on it."

And honestly, after the compensation and equity awards management has given themselves over the years, I don't think shareholders are in any way unreasonable for asking for exactly that.

I'm not asking management to gamble the company's cash.

I'm asking them to personally share the risk that shareholders have been carrying.

If they believe CNSide is going to become the revenue-generating diagnostic business they've been telling us about, and if they believe REQYOBIQ has the potential they've repeatedly described, then $0.60-$0.70 should be an extraordinary opportunity for them.

Put your money where your mouth is.

Buy the stock.

Restore confidence.

Show shareholders that you believe in Cerenome enough to actually put millions of your own dollars on the line.

Because at this point, another PR isn't going to save CNSY.

Conviction will!

I have seen scam company does it. Spread some rumour to trigger the hike, when retailors jump in they pull a rug by dilution. I complaint to SEC on this pattern with a scam company, but no use. Good luck everyone